Market Research Reports

Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

98pages
Published Date: 2013-10-21
 

Description





This report studies the global erectile dysfunction drugs market with a major focus on the branded drugs which include Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil) and others such as MUSE (Medicated Urethral System for Erections), Mvix and Helleva. Pipeline analysis for drugs namely, Vitaros (alprostadil), Uprima (apomorphine) and few others have also been included in the report. Market size and forecasts for the period 2010 – 2019 have been provided for each of the drugs, in terms of USD million, considering historical data for 2010 and 2011, and base year as 2012. The % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 - 2019 has also been provided along with market size estimations.

Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). The respective market size and forecast till 2019 for each region has also been presented in the report along with the CAGR. In addition, the market overview section of the report provides a qualitative assessment of the market dynamics wherein the drivers, restraints, and opportunities along with market attractiveness and Porter’s Five Forces analysis have been studied.
 
The competitive landscape section includes market share analysis of the leading players in the branded drugs market for erectile dysfunction treatment, in terms of percentage share in the year 2012. Some of the major players profiled in this report include Pfizer, Inc., Eli Lilly and Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd., and Vivus, Inc.

Table of Contents




Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction to Erectile Dysfunction
3.2 Current Market Trends and Future Outlook
      3.2.1 Impact of Generics
      3.2.2 Key Patent Expirations
      3.2.3 Ongoing Clinical Trials in the U.S. for ED Treatment (Phase III)
3.3 Types of Treatments for ED
      3.3.1 Phosphodiesterase Type 5 Inhibitors (PDE 5 Inhibitors)
      3.3.2 Localized Therapy
      3.3.3 Testosterone Replacement Therapy
      3.3.4 Vacuum Constriction Devices
      3.3.5 Surgery (Penile Implants and Vascular Surgery)
      3.3.6 Alternative Medicines (Yohimbine and Other Herb and Dietary Supplements)
3.4 Market Drivers
      3.4.1 Increase in Elderly Population
      3.4.2 Increasing Global Incidence of Various Diseases and Growing Preference Towards Sedentary Lifestyle
      3.4.3 Increase in Awareness and Patient Education
3.5 Market Restraints
      3.5.1 Prevalence of Sexually Transmitted Diseases with ED Drug Users
      3.5.2 Narrowing of Insurance Coverage for Erectile Dysfunction Treatment
      3.5.3 Growing Threat from Counterfeit Drugs
3.6 Market Opportunities
      3.6.1 Novel Molecule Combinations and Drug Delivery Techniques are Expected to Become a Rising Opportunity
      3.6.2 Generics - A Growing Global Opportunity
3.7 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs Market
      3.7.1 Bargaining Power of Suppliers
      3.7.2 Bargaining Power of Buyers
      3.7.3 Threat of Substitutes
      3.7.4 Threat of New Entrants
      3.7.5 Competitive Rivalry
3.8 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)

Chapter 4 Global Erectile Dysfunction Drugs Market Revenue, By Brand, 2011-2019 (USD Million)
4.1 Market Overview
      4.1.1 Mechanism of Action
      4.1.2 Characteristics of Major Phosphodiesterase Type 5 Inhibitors
4.2 Viagra (Sildenafil Citrate)
      4.2.1 Introduction
      4.2.2 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.2.3 Patent Expiration and Regulatory Scenario
              4.2.3.1 The U.S. Market
              4.2.3.2 International Market
      4.2.4 Past & Current Market Scenario
      4.2.5 Global Viagra Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.2.6 Future Market Scenario
      4.2.7 Global Viagra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.3 Cialis (Tadalafil)
      4.3.1 Introduction
      4.3.2 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.3.3 Patent and Regulatory Scenario
      4.3.4 Current Market Scenario and Patent Expiry Effect
      4.3.5 Global Cialis Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.3.6 Future Market Scenario
      4.3.7 Global Cialis Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.4 Levitra/Staxyn (Vardenafil)
      4.4.1 Introduction
      4.4.2 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.4.3 Patent and Regulatory Scenario
      4.4.4 Current and Future Market Scenario
      4.4.5 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.4.6 Global Levitra/Staxyn Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.5 Stendra/Spedra (Avanafil)
      4.5.1 Introduction
      4.5.2 Future Market Scenario
      4.5.3 Global Stendra/Spedra Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.6 Zydena (Udenafil)
      4.6.1 Introduction
      4.6.2 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
      4.6.3 Current Market Scenario
      4.6.4 Global Zydena Market for Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
      4.6.5 Future Market Scenario
      4.6.6 Global Zydena Market for Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
4.7 MUSE (Medicated Urethral System for Erection)
      4.7.1 Patent and Regulatory Scenario
4.8 Mvix (Mirodenafil)
4.9 Helleva (Lodenafil Carbonate)

Chapter 5 Global Erectile Dysfunction Drugs Market, Pipeline Analysis
5.1 Overview
5.2 Vitaros (Alprostadil)
      5.2.1 Global Vitaros Market for Erectile Dysfunction Treatment, 2014 – 2019 (USD Million)
5.3 Uprima (Apomorphine)
5.4 Others (Topiglan, Melanocortin Activators, Gene Therapy)
      5.4.1 Topiglan
      5.4.2 Melanocortin Activators
      5.4.3 Gene Therapy

Chapter 6 Global Erectile Dysfunction Drugs Market, By Geography
6.1 Overview
      6.1.1 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2019 (USD Million)
      6.1.2 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019 (Value %)
6.2 North America
      6.2.1 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.2.2 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
6.3 Europe
      6.3.1 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.3.2 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
6.4 Asia-Pacific
      6.4.1 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.4.2 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
6.5 Rest of the World (Row)
      6.5.1 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
      6.5.2 Rest of the World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million)

Chapter 7 Competitive Landscape
7.1 Market Share Analysis: Global Erectile Dysfunction Drugs Market, 2012 (%)
      7.1.1 Methodology
      7.1.2 Analysis

Chapter 8 Recommendations
8.1 Novel Drug Formulations and Genericization owing to Patent Expiration of well recognized ED Drugs
8.2 Mergers and Acquisitions to Strengthen Market Presence
8.3 Cost Containment Measures

Chapter 9 Company Profiles
9.1 Apricus Biosciences, Inc.
      9.1.1 Company Overview
      9.1.2 Business Strategies
      9.1.3 Financial Overview
      9.1.4 Product Portfolio
      9.1.5 Recent Developments
9.2 Bayer AG
      9.2.1 Company Overview
      9.2.2 Business Strategies
      9.2.3 Financial Overview
      9.2.4 Product Portfolio
      9.2.5 Recent Developments
9.3 Cristalia Produtos Quimicos Farmaceuticos Ltda.
      9.3.1 Company Overview
      9.3.2 Business Strategies
      9.3.3 Product Portfolio
      9.3.4 Recent Developments
9.4 Dong-A Pharmaceutical Co. Ltd.
      9.4.1 Company Overview
      9.4.2 Business Strategies
      9.4.3 Financial Overview
      9.4.4 Product Portfolio
      9.4.5 Recent Developments
9.5 Eli Lilly And Company
      9.5.1 Company Overview
      9.5.2 Business Strategies
      9.5.3 Financial Overview
      9.5.4 Product Portfolio
      9.5.5 Recent Developments
9.6 Meda Pharmaceuticals, Inc.
      9.6.1 Company Overview
      9.6.2 Business Strategies
      9.6.3 Product Portfolio
      9.6.4 Recent Developments
9.7 Pfizer, Inc.
      9.7.1 Company Overview
      9.7.2 Business Strategies
      9.7.3 Financial Overview
      9.7.4 Product Portfolio
      9.7.5 Recent Developments
9.8 S.K. Chemicals Co. Ltd.
      9.8.1 Company Overview
      9.8.2 Business Strategies
      9.8.3 Financial Overview
      9.8.4 Product Portfolio
      9.8.5 Recent Developments
9.9 Vivus, Inc.
      9.9.1 Company Overview
      9.9.2 Business Strategies
      9.9.3 Financial Overview
      9.9.4 Product Portfolio
      9.9.5 Recent Developments

List of Figures

FIG. 1 Erectile Dysfunction Drugs Market Segmentation
FIG. 2 Global Erectile Dysfunction Drugs Market Revenue, 2010 - 2019 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Erectile Dysfunction Drugs Market
FIG. 4 Market Attractiveness Analysis: Global Erectile Dysfunction Drugs Market, By Geography (2015)
FIG. 5 PPDE 5 Inhibitors: Mechanism of Action
FIG. 6 Global Viagra Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 7 Global Viagra Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 8 Global Viagra Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 9 Global Cialis Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 10 Global Cialis Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 11 Global Cialis Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 12 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 13 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 14 Global Levitra/Staxyn Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 15 Global Stendra/Spedra Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 16 Global Zydena Market For Erectile Dysfunction Treatment, 2010 – 2019 (USD Million)
FIG. 17 Global Zydena Market For Erectile Dysfunction Treatment, 2010 – 2014 (USD Million)
FIG. 18 Global Zydena Market For Erectile Dysfunction Treatment, 2015 – 2019 (USD Million)
FIG. 19 Global Vitaros Market For Erectile Dysfunction Treatment, 2014 – 2019 (USD Million)
FIG. 20 Comparative Analysis: Global Erectile Dysfunction Drugs Market, By Geography, 2012 & 2019 (Value %)
FIG. 21 North America Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 22 North America Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
FIG. 23 Europe Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 24 Europe Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
FIG. 25 Asia-Pacific Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 26 Asia-Pacific Erectile Dysfunction Drugs Market, 2015 - 2019 (USD Million)
FIG. 27 Rest Of The World (Row) Erectile Dysfunction Drugs Market, 2010 – 2014 (USD Million)
FIG. 28 Rest Of The World (Row) Erectile Dysfunction Drugs Market, 2015 – 2019 (USD Million)
FIG. 29 Market Share By Key Players: Branded Formulations For Erectile Dysfunction Treatment, 2012 (%)
FIG. 30 Apricus Biosciences, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 31 Bayer AG: Annual Revenue, 2010 – 2012 (USD Million) (1 Euro = 1.35 USD)
FIG. 32 Dong-A Pharmaceutical Co. Ltd.: Annual Revenue, 2010 – 2012 (USD Million) (1 KRW = 0.0093 USD)
FIG. 33 Eli Lilly & Co.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 34 Pfizer, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 35 S. K. Chemicals Co. Ltd.: Annual Revenue, 2010 – 2012 (USD Million) (1 KRW = 0.0093 USD)

List of Tables

TABLE 1 Market Snapshot: Global Erectile Dysfunction Drugs Market
TABLE 2 Causes Of Erectile Dysfunction
TABLE 3 Ongoing Clinical Trials In The U.S. For ED Treatment (Phase III)
TABLE 4 Causes Of ED: Classes Of Drugs Used To Treat Chronic Diseases
TABLE 5 Global Erectile Dysfunction Drugs, 2010 – 2014 (USD Million)
TABLE 6 Global Erectile Dysfunction Drugs, 2015 – 2019 (USD Million)
TABLE 7 Characteristics Of PDE 5 Inhibitor Class Of Erectile Dysfunction Drugs
TABLE 8 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2010 – 2014 (USD Million)
TABLE 9 Global Erectile Dysfunction Drugs Market Revenue, By Geography, 2015 – 2019 (USD Million)

Enquiry Before Buying




Free Market Analysis





Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs. Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies. 

Erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market.

Pfizer’s Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG. 

Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. The North American market for erectile dysfunction drugs was valued at USD 2,098.4 million in the year 2012. However, loss of patent exclusivities for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) within the forecast period are expected to hamper market growth, though to a lesser extent. Factors such as increased market consolidation (due to influx of generics and weak pipeline development), cost containment measures coupled with introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets. The leading players in the market for branded erectile dysfunction drugs are Pfizer, Inc., Eli Lilly & Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus, Inc.

global-erectile-dysfunction-drugs-market-revenue-2010-2019
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research